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Abstract Systemic therapies have been shown to effec-
tively improve prognosis in patients with breast cancer.
However, such therapies also become increasingly harmful
as their duration increases, and they have adverse effects
on fertility and ovarian function. Fertility preservation (FP)
is important in young adult cancer survivors who may wish
to have children. In Japan, some cancer societies recom-
mend that the potentially serious effects of systemic ther-
apy on ovarian function should be explained to women
with cancer, and they should be encouraged to undergo
FP prior to commencing treatment. Still, as there are no
official guidelines, many oncologists lack the required
knowledge and mind-set to advise young breast cancer
patients on fertility issues. Counseling of patients and their
families might improve their understanding about the
influence of such treatment on fertility and ensure effective
FP. There are several FP methods that can be selected
before beginning treatment, and these methods have both
advantages and disadvantages. Young adults with breast
cancer who want to bear children in the future must be
provided with FP counseling, in addition to advice about
breast cancer treatment and prognosis.
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Introduction
In 1986, the National Coalition for Cancer Survivorship
(NCCS) defined living patients after cancer diagnosis as
cancer survivors; survivors need numerous supportive mea-
sures because of the many social problems that they face,
and these measures would greatly influence their families
and friends [1]. These problems differ among individuals
depending on their social background; therefore, provision of
support cannot be based on any standard guidelines. Recently,
the importance of cancer survivorship has received recogni-
tion owing to the needs of these patients. Oncologists should
consider appropriate and more effective treatment strategies
according to the individual’s needs and social background.
The number of breast cancer patients, including those
younger than 40 years of age and premenopausal patients
who want to bear children, is increasing every year in
Japan. Young patients often have a good prognosis and live
long recurrence-free lives following systemic therapy for
breast cancer. However, the treatments employed exert
many physical and psychological effects on young patients
who hold important positions in their societies and fami-
lies. In addition, the influence of the treatment on fertility
and the fetus is of great importance to young cancer sur-
vivors who wish to start a family.
In contrast, an increasing number of women are mar-
rying late in life, and advances in the field of perinatal and
reproductive medicine have improved the safety of infer-
tility treatment. Therefore, advanced reproductive tech-
niques can be used in patients receiving systemic therapy
who want to have children after breast cancer treatment.
However, there are numerous important questions that need
to be resolved by the collaborative efforts of oncologists
and gynecologists before cancer survivors are encouraged
to proceed with fertility preservation (FP).
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Influence of systemic therapy for breast cancer
on fertility
Chemotherapy influences the ovarian function and induces
amenorrhea. The frequency of chemotherapy-induced
amenorrhea (CIA) differs according to the patient age and
the chemotherapy regimen administered. The rate of irre-
versible CIA increases with the advancing age of the
patient [2, 3]. The reported rates of CIA associated with the
use of AC (anthracycline and cyclophosphamide) and CMF
(cyclophosphamide, methotrexate, and 5-FU) are 30–50 %
and 40–70 %, respectively. The risk of CIA increases with
the addition of taxane in patients over 40 years of age
[4, 5]. One very important issue that needs to be resolved is
the lack of data on the rate of normal pregnancy or delivery
after recovery from CIA in breast cancer survivors, and
also on ovarian function after systemic therapy, which
varies among patients of different races and environments.
It is unclear if the data reported from European countries
can be applied to Japanese patients.
Recently anti-mu¨llerian hormone and inhibin B have
been used as markers of ovarian function [6, 7]. Data need
to be collected on Japanese patients and these (or other
new) markers must be used to predict the reserve ovarian
function after systemic therapy. In young patients receiving
endocrine therapy after the primary operation who wish to
bear children in the future, it would be very useful and
important to clarify ovarian function after 5 years of
treatment.
Trend of FP in cancer patients
The practice of FP among cancer patients is closely related
to the social background of the patients and entails several
ethical problems. In Japan, embryo preservation among
partners who are not married is not permitted. Age and
prognosis are important considerations for FP. However,
there are as yet no appropriate guidelines or consensus.
Nevertheless, FP technologies and cancer therapy are
improving every day, and the number of cancer survivors
who want to have children is also increasing. Several
Japanese hematologic and oncologic societies recommend
the provision of accurate information concerning the influ-
ence of chemotherapy on fertility and FP to cancer patients
and their families. In 2004, the Japan Society of Clinical
Oncology, the Japan Society of Obstetrics and Gynecology,
and the Japanese Urological Association suggested that
oncologists and gynecologists should provide a thorough FP
explanation to breast cancer patients before the start of
systemic and radiation therapy. The Japan Society for
Hematopoietic Cell Transplantation expressed concerns
about giving their patients’ information (present technology
and the limits of FP) to all members in 2005. This trend is
similar to that observed in the USA. To assist healthcare
professionals to inform their patients about FP, several
national organizations, including the President’s Cancer
Panel (2004), the American Society of Reproductive
Medicine Ethics Committee (2005), and the American
Society of Clinical Oncology (2006) [8], published FP
guidelines [9]. The multi-institutional trial of oocyte cryo-
preservation for unmarried hematological cancer patients by
A-PART (The International Association of Private Assisted
Reproduction of Technology Clinics and Laboratories)
started in Japan in 2007 (http://www.apartonline.info/japan/).
At the present time, Japanese cancer societies only
recommend the ‘‘provision of appropriate information’’ to
young patients, and there is no guiding principle or stan-
dard method for FP, which often involves special proce-
dures that patients cannot receive at every hospital with
public insurance in Japan. Moreover, the legal aspects of
the ethical problems related to preservation of oocytes and
sperm have not yet been discussed, and are only auto-
regulated by the relevant societies in Japan.
Current status of FP and counseling for breast cancer
patients in Japan
The Japanese Breast Cancer Society and Clinical Practice
Guidelines for Breast Cancer do not yet provide definitive
recommendations for Japanese breast oncologists regarding
FP for young breast cancer patients. In a previous report,
significantly fewer patients expressed an interest in fertility
when they had children or advanced disease, and patients
with less aggressive treatment were recommended FP by
oncologists [10]. However, from the results of our survey
[11], the patient’s desire to give birth does not always
depend on the number of children they have, age, and
marital status, and we need to confirm their wishes indi-
vidually before commencing treatment. We thought it
necessary to establish a counseling system under which
information can be supplied efficiently to breast cancer
patients requiring FP, ensuring that patients who want to
have children could undergo FP before receiving appro-
priate treatment for their breast cancer. Shimizu et al. [12]
reported the results of a national survey on this problem,
and many Japanese oncologists lacked the necessary
knowledge and mind-set to advise young breast cancer
patients on fertility issues. The barriers to discussing FP
were risk of recurrence, lack of collaborating reproductive
specialists, and time constraints in the clinic. Therefore, it
is necessary to develop a comprehensive and interdisci-
plinary program for healthcare providers.
Many young cancer patients with breast cancer have
little knowledge of fertility issues. This lack of knowledge
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is associated with increased decisional conflict; targeted
and timely fertility information may reduce the patients’
concerns and increase informed choice [13]. However, this
is very difficult for oncologists alone to achieve, and spe-
cialist teams in fertility counseling are needed.
Details of FP
Measures to reduce ovarian disorders caused
by treatment
A gonadotropin-releasing hormone (GnRH) agonist is
administered for a short period to suppress ovulation and to
prevent reduction in ovarian function. Approximately
2 weeks after the start of the GnRH agonist treatment, the
effect of the agonist in suppressing oocyte maturation begins
to become apparent, making the oocytes less sensitive to
chemotherapy. As it takes approximately 2–3 weeks for this
effect to manifest, the GnRH agonist needs to be adminis-
tered in a well-planned manner before the start of treatment
for the malignant disease [14]. There are some ongoing
studies to determine the exact nature of this process. The
ZORO multicenter study reported in 2011 that there was no
significant effect of GnRH on ovarian function after adjuvant
chemotherapy [15]. There is no evidence for the validity of
this technique as a tool for FP, and current guidelines do not
recommend its use [16], even though it has been suggested to
have the potential to reduce the likelihood of CIA [15].
Storing frozen oocytes or ovarian tissue
before the start of treatment
The validity of the measures taken for reducing ovarian
disorders during treatment or post-treatment measures to
deal with the loss of ovarian function is essentially limited,
when their relationship to the malignant disease or its
treatment is taken into account. The most promising
approach is frozen storage of the patient’s oocytes or
ovarian tissue collected before the start of systemic treat-
ment. At present, research into this technology is underway
with the aim of establishing a reliable system. Table 1
shows the details of each method proposed for storing
oocytes and ovarian tissue. Although procedures for pre-
serving of oocytes or the ovarian tissue itself are available,
the collection of oocytes and/or ovarian tissue requires a
preparatory period and involves physical stress (puncture
and operation). Recent optimal success rates per cycle are
reported to be in the 30–40 % range or higher per embryo
transfer. According to the American Society of Repro-
ductive Medicine (ASRM), on the basis of published peer-
reviewed medical literature, there is an approximate overall
2 % live-birth rate per oocyte thawed for cryopreservation
by using the older slow-freeze methods. There is an
approximate overall 4 % live-birth rate per oocyte thawed
for cryopreservation by using vitrification. However,
pregnancy rates as high as 8 % per frozen egg (on average
12.4 eggs needed per pregnancy) have been achieved at
centers using some of the newer freeze methods such
as LANDA (http://donor-egg-program-utah.fertilitydr.com/
egg-freezing-overview.html).
Oocyte preservation can be accomplished by either
oocyte cryopreservation or embryo cryopreservation. In
general, the oocyte is more susceptible to damage caused
by cryopreservation, and fertility is lower with oocyte
cryopreservation than with embryo cryopreservation.
For married women, storage of embryos after in vitro
fertilization is possible. For unmarried women, however,
unfertilized oocytes must be selected because of the
unavailability of sperm from a fixed partner. In recent
years, following active research and development on the
methods for cryopreservation and storing of unfertilized
oocytes, the number of facilities providing such services
has increased worldwide [17, 18]. In Japan, the first such
attempt was reported in 2001 (for a married couple who
successfully bore a child using this technique).
These techniques involve two major problems when
applied to breast cancer patients. The first problem pertains to
Table 1 Fertility preservation
options for breast cancer
patients
IVF-ET in vitro fertilization and
embryo transfer
Option
Oocyte freezing Embryo freezing Ovarian tissue freezing
Method Ovarian puncture Ovarian puncture Laparoscopic surgery
Depending on menstruation Yes Yes No
Delay of cancer treatment 3–4 weeks 3–4 weeks Several days
Follicle stimulation Necessary Necessary Unnecessary
Number of preservation eggs 1–10 1–10 Many
Partner sperm Unnecessary Necessary Unnecessary
IVF-ET Necessary Necessary Unnecessary
Implantation of cancer cell No No Yes
Success rate 10–30 % 10–40 % Unestimated
Breast Cancer (2014) 21:651–655 653
123
the use of follicle stimulation to facilitate oocyte collection
and can cause elevation of blood estrogen levels, even if only
temporarily. In healthy women, this manipulation has not
been considered to have the potential to increase the risk of
breast cancer, gynecologic cancers, etc. [19–21], and preg-
nancy after estrogen receptor (ER)-positive breast cancer
does not seem to increase the risk of recurrence [22]; how-
ever, the influence of follicle stimulation on the prognosis of
ER-positive breast cancer patients is unclear [23, 24]. The
special follicle stimulation method for breast cancer or its
treatment is being examined, but as it is still at the stage of
basic research, no clinical evidence has been obtained yet
[25]. At present, it is recommended that this procedure
should be done after completion of at least local surgery.
The second problem pertains to the timing of the FP,
which should be planned without affecting the cancer
treatment plan. To collect oocytes, follicle stimulation takes
place according to a schedule that matches the menstrual
cycle of each patient. Therefore, in some cases, approxi-
mately a month may be needed to collect oocytes depending
on the menstrual cycle. Thus, adjustment of the timing of
treatment and FP may be difficult in cases where the treat-
ment is urgently needed. It is, therefore, difficult to set aside
a period for FP before preoperative chemotherapy in cases of
local advanced breast cancer that require prompt treatment.
As the breast cancer treatment strategy is highly influenced
by the FP procedure, oncologists need to be conscious of the
patient’s desire to bear children before the start of treatment.
Ovarian tissue cryopreservation has begun to attract
attention as a new approach [26]. Its main advantages are
that it does not involve follicle stimulation and that it
enables preservation by a quick collection of a part of the
ovary by an obstetrician/gynecologist at a facility where
laparoscopic surgery is possible. This approach obviates
the need for adjustment of treatment time and scheduling
according to the patient’s menstrual cycle. If the stored
ovarian tissue is implanted subcutaneously into the fore-
arm, abdominal wall, etc., additional procedures such as
in vitro fertilization and embryo transfer (IVF-ET) would
be needed. However, if it is implanted laparoscopically
onto a site near the oviduct, spontaneous pregnancy can be
expected. However, according to reports, care needs to be
taken for the possible presence of tumor cells in the ovarian
tissue [27]. In Japan, clinical research on the storage of
ovarian tissue has been ongoing at Okayama University
since 2005. Although there are ethical and technical
aspects that must be resolved before it can be widely
adopted in Japan, this approach is promising in view of the
following features: (1) If the thawed ovarian tissue survives
after implantation, pregnancy and secretion of female
hormones can be expected; (2) follicle stimulation is
unnecessary; and (3) a larger number of stored oocytes can
be obtained, possibly elevating the fertility rate.
Conclusion
The demand for provision of FP to young adult breast
cancer patients receiving systemic therapy is increasing,
and FP techniques are steadily improving. It is very diffi-
cult to decide the eligibility of breast cancer patients for FP
because of differences in the individual’s situation and
environment. Therefore, an active counseling system tai-
lored to each patient must be devised by the respective
attending specialists. There are many unresolved technical,
ethical, and social problems in this field. We must provide
appropriate explanations of these issues to young adult
breast cancer patients who want to have children and make
appropriate treatment plans to preserve their fertility, in
addition to explaining the cancer treatment and outcomes
to these patients.
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